{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:48:59Z","timestamp":1776779339676,"version":"3.51.2"},"reference-count":109,"publisher":"Impact Journals, LLC","issue":"64","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,8,17]]},"DOI":"10.18632\/oncotarget.25892","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T14:35:00Z","timestamp":1534516500000},"page":"32383-32399","source":"Crossref","is-referenced-by-count":12,"title":["Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"first","affiliation":[{"name":"Department of Hematology, Institut Catal\u00e0 d' Oncologia and IDIBELL, L' Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Spanish Lymphoma Group (GELTAMO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Coronado","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Hematology, MD Anderson Cancer Center, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Montes-Moreno","sequence":"additional","affiliation":[{"name":"Department of Pathology and Translational Hematopathology Lab, Hospital Universitario Marqu\u00e9s de Valdecilla\/IDIVAL, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cl\u00ednica Universidad de Navarra and Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario Vall d'Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"1","unstructured":"Montes-Moreno, Mollejo Villanueva, Fraga, Garc\u00eda, Villar, Mart\u00ednez, Rodr\u00edguez Pinilla, Battle, Pulla, Rozman, Garc\u00eda Sanz. Recomendaciones para el estudio histopatol\u00f3gico, inmunohistoqu\u00edmico, citogen\u00e9tico y molecular e informe diagn\u00f3stico de los procesos neopl\u00e1sicos linfoides. Consenso SEAP-SEHH-GOTEL. En: Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a. 2017; pp. 63\u2013174. Available at: https:\/\/www.seap.es\/libros-blancos."},{"key":"2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Marti","year":"2000","journal-title":"Nature"},{"key":"3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy","volume":"15","author":"Fu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Meyer","year":"2012","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"M\u00f8ller","year":"2012","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Chiu","year":"2013","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.13085","article-title":"CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia","volume":"167","author":"Gascoyne","year":"2014","journal-title":"Br J Haematol"},{"key":"9","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Orazi","year":"2013","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","volume":"33","author":"Telenius","year":"2015","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Kluin","year":"2011","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u2018double hit\u2019 diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Lister","year":"2014","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Connors","year":"2007","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Czuczman","year":"2014","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b22 -microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Salar","year":"2017","journal-title":"Br J Haematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Lee","year":"2011","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood-2012-08-450106","article-title":"Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma","volume":"121","author":"Gray","year":"2013","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Nastoupil","year":"2014","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma","volume":"339","author":"Fisher","year":"1998","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Reyes","year":"2007","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Le_Gouill","year":"2018","journal-title":"Blood"},{"key":"24","unstructured":"German High-Grade Non-Hodgkin's Lymphoma Study Group. Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma January 18 2006. Available 2017 Nov 16, from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00278408."},{"key":"25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Bosly","year":"2005","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Ho","year":"2008","journal-title":"Lancet Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Kruger","year":"2013","journal-title":"Lancet"},{"key":"29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Casasnovas","year":"2013","journal-title":"Lancet Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","volume":"126","author":"Rizo","year":"2015","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma","volume":"32","author":"R\u00fcbe","year":"2014","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Shpilberg","year":"2006","journal-title":"Lancet Oncol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Kvaloy","year":"2011","journal-title":"Lancet Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Bologna","year":"2011","journal-title":"Lancet"},{"key":"36","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","article-title":"Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte\/lymphoma study association phase III trial LNH 03-2B","volume":"32","author":"Leroy","year":"2014","journal-title":"J Clin Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.13273","article-title":"Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group","volume":"169","author":"Ferrando-Lamana","year":"2015","journal-title":"Br J Haematol"},{"key":"38","doi-asserted-by":"crossref","first-page":"469LP","DOI":"10.1182\/blood.V128.22.469.469","article-title":"Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB\/Alliance 50303","volume":"128","author":"Abramson","year":"2016","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma","volume":"369","author":"Marcellus","year":"2013","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Bordessoule","year":"2011","journal-title":"Lancet Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial","volume":"32","author":"Cunnningham","year":"2014","journal-title":"J Clin Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","article-title":"Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial","volume":"21","author":"Federico","year":"2010","journal-title":"Ann Oncol"},{"key":"43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial","volume":"15","author":"Kwak","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"44","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma","volume":"333","author":"Mandelli","year":"1995","journal-title":"N Engl J Med"},{"key":"45","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"46","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12","volume":"32","author":"Baetz","year":"2014","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GELTAMO study","volume":"93","author":"Donato","year":"2008","journal-title":"Haematologica"},{"key":"48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study","volume":"35","author":"Lepp\u00e4","year":"2017","journal-title":"J Clin Oncol"},{"key":"49","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.23861","article-title":"Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma","volume":"113","author":"Zinzani","year":"2008","journal-title":"Cancer"},{"key":"50","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"key":"51","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III Randomized Study of Rituximab\/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab\/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial","volume":"31","author":"Tomblyn","year":"2013","journal-title":"J Clin Oncol"},{"key":"52","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Hagberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"53","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1200\/JCO.2004.09.092","article-title":"Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation","volume":"22","author":"Khouri","year":"2004","journal-title":"J Clin Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma","volume":"27","author":"Mackinnon","year":"2009","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"Ossenkoppele","year":"2011","journal-title":"J Clin Oncol"},{"key":"56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1148\/radiol.2015142556","article-title":"Prognostic Value of FDG PET\/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma","volume":"277","author":"Zelenetz","year":"2015","journal-title":"Radiology"},{"key":"57","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Maurer","year":"2017","journal-title":"Blood"},{"key":"58","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Ysebaert","year":"2011","journal-title":"J Clin Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"60","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial","volume":"98","author":"Salles","year":"2013","journal-title":"Haematologica"},{"key":"61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Lynam","year":"2014","journal-title":"Ann Hematol"},{"key":"62","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Kuepfer","year":"2012","journal-title":"Lancet Oncol"},{"key":"63","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Czuczman","year":"2011","journal-title":"Ann Oncol"},{"key":"64","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12449","article-title":"Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation","volume":"162","author":"Witzig","year":"2013","journal-title":"Br J Haematol"},{"key":"65","first-page":"10705","article-title":"Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis","volume":"8","author":"Jiang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1658-3876(10)50051-7","article-title":"A phase II study of high-dose celecoxib and metronomic \u2018low-dose\u2019 cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma","volume":"3","author":"El_Mageed","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"67","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Leonard","year":"2008","journal-title":"Cancer"},{"key":"68","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"O'Doherty","year":"2014","journal-title":"J Clin Oncol"},{"key":"69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning","volume":"15","author":"Swinnen","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.13036","article-title":"Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial","volume":"167","author":"P\u00e9rez-Ceballos","year":"2014","journal-title":"Br J Haematol"},{"key":"71","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma","volume":"32","author":"Peix","year":"2014","journal-title":"J Clin Oncol"},{"key":"72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2016.149120","article-title":"Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)","volume":"102","author":"Orfao","year":"2017","journal-title":"Haematologica"},{"key":"73","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Rule","year":"2015","journal-title":"Br J Haematol"},{"key":"74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Bishop","year":"2004","journal-title":"Br J Haematol"},{"key":"75","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2014results of a multicenter phase III study","volume":"28","author":"Brown","year":"2010","journal-title":"J Clin Oncol"},{"key":"76","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","article-title":"Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia","volume":"37","author":"Mehta","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"77","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Miranda","year":"2015","journal-title":"Blood"},{"key":"78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-Negative Plasmablastic Lymphoma: Not in the Mouth","volume":"11","author":"Butera","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"79","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Seegmiller","year":"2012","journal-title":"Cancer"},{"key":"80","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma","volume":"15","author":"Butera","year":"2010","journal-title":"Oncologist"},{"key":"81","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: a review","volume":"20","author":"Re","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience","volume":"56","author":"Rossi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"83","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.leukres.2011.06.023","article-title":"Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review","volume":"35","author":"Raychaudhuri","year":"2011","journal-title":"Leuk Res"},{"key":"84","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Winer","year":"2015","journal-title":"Br J Haematol"},{"key":"85","first-page":"1","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients","volume":"57","author":"Sancho","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"86","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Wilson","year":"2013","journal-title":"N Engl J Med"},{"key":"87","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ctrv.2015.04.006","article-title":"Primary mediastinal large B-cell lymphoma","volume":"41","author":"Armitage","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"88","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Ho","year":"2011","journal-title":"Ann Oncol"},{"key":"89","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3109\/10428194.2012.746684","article-title":"Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy","volume":"54","author":"Li","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"90","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajh.24172","article-title":"Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis","volume":"90","author":"Armitage","year":"2015","journal-title":"Am J Hematol"},{"key":"91","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients","volume":"87","author":"Ferreri","year":"2002","journal-title":"Haematologica"},{"key":"92","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11899-014-0219-0","article-title":"Primary mediastinal large B-cell lymphoma","volume":"9","author":"Walewski","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"93","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Crump","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"94","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas","volume":"16","author":"Coiffier","year":"2015","journal-title":"Lancet Oncol"},{"key":"95","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.11305","article-title":"The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement","volume":"92","author":"Avet-Loiseau","year":"2007","journal-title":"Haematologica"},{"key":"96","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Hirano","year":"2009","journal-title":"Leukemia"},{"key":"97","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V124.21.395.395","article-title":"Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma","volume":"124","author":"Staudt","year":"2014","journal-title":"Blood"},{"key":"98","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Mato","year":"2015","journal-title":"Br J Haematol"},{"key":"99","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation","volume":"35","author":"Brown","year":"2017","journal-title":"J Clin Oncol"},{"key":"100","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Melinamani","year":"2014","journal-title":"Blood"},{"key":"101","first-page":"704","article-title":"The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy","volume":"90","author":"Feliu","year":"2005","journal-title":"Haematologica"},{"key":"102","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV\u2212 non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Genet","year":"2009","journal-title":"Blood"},{"key":"103","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/00002030-200304110-00011","article-title":"Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma","volume":"17","author":"Bower","year":"2003","journal-title":"AIDS"},{"key":"104","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(\u2605)","volume":"11","author":"Tsai","year":"2011","journal-title":"Am J Transplant"},{"key":"105","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"de_Sevilla","year":"2007","journal-title":"Haematologica"},{"key":"106","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Lamy","year":"2012","journal-title":"Lancet Oncol"},{"key":"107","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"MacGilchrist","year":"2007","journal-title":"Blood"},{"key":"108","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Handgretinger","year":"2013","journal-title":"J Clin Oncol"},{"key":"109","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/ajt.12640","article-title":"Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation","volume":"14","author":"Leblond","year":"2014","journal-title":"Am J Transplant"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T19:18:44Z","timestamp":1589051924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":109,"journal-issue":{"issue":"64","published-print":{"date-parts":[[2018,8,17]]}},"alternative-id":["25892","30190794"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25892","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]}}}